Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...
The BC Cancer Foundation has launched a $6.8 million fundraising campaign to expand provincial immunotherapy research program ...
The US regulator has approved Aucatzyl (obecabtagene autoleucel or obe-cel) for the treatment of adults with relapsed or refractory B-cell precursor ... including mantle cell lymphoma (MCL).
Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...
The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...
When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response in the region changes, researchers report. The detailed insights into cancer ...
A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
News Medical on MSN11h
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancerRegeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback